Evidence map›Paper›PMID 42156779›Full record

ArticleScientific data2026

Multimodal ultra-high-field MRI, clinical, cognitive, and genetic profiles across the ALS-FTD spectrum.

Thomas B Shaw, Aiman Al Najjar, Markus Barth, Steffen Bollmann, Pierrick Bourgeat, Jeryn Chang, Harriet Dempsey-Jones, Amir Fazlollahi, Jurgen Fripp, Natalie Garden and 15 more

Abstract readDataset
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific data, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Thomas B ShawSchool of Electrical Engineering and Computer Science, The University of Queensland, Brisbane, Australia. t.shaw@uq.edu.au.
Aiman Al NajjarCentre for Advanced Imaging, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Australia.
Markus BarthSchool of Electrical Engineering and Computer Science, The University of Queensland, Brisbane, Australia.
Steffen BollmannSchool of Electrical Engineering and Computer Science, The University of Queensland, Brisbane, Australia.
Pierrick BourgeatAustralian e-Health Research Centre, CSIRO Health and Biosecurity, Herston, Queensland, Australia.
Jeryn ChangSchool of Biomedical Sciences, The University of Queensland, Brisbane, Australia.
Harriet Dempsey-JonesSchool of Psychology, The University of Queensland, Brisbane, Australia.
Amir FazlollahiQueensland Brain Institute, The University of Queensland, Brisbane, Australia.
Jurgen FrippAustralian e-Health Research Centre, CSIRO Health and Biosecurity, Herston, Queensland, Australia.
Natalie GardenQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Christine C GuoAmetris, Pensacola, FL, USA.
Robert D HendersonRoyal Brisbane and Women's Hospital, Neurology Dept., Brisbane, Australia.
Elaine KuanSchool of Electrical Engineering and Computer Science, The University of Queensland, Brisbane, Australia.
Jinglei LvSydney Medical School, School of Biomedical Engineering, The University of Sydney, Sydney, Australia.
Pamela A McCombeRoyal Brisbane and Women's Hospital, Neurology Dept., Brisbane, Australia.
Aswin NarayananCentre for Advanced Imaging, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Australia.
Shyuan T NgoRoyal Brisbane and Women's Hospital, Neurology Dept., Brisbane, Australia.
Vinh NguyenQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Kieran O'BrienSiemens Healthcare Pty Ltd, Brisbane, Australia.
Gail RobinsonSchool of Psychology, The University of Queensland, Brisbane, Australia.
Simon RobinsonHigh Field MR Center, Department for Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
Olivier SalvadoQueensland University of Technology, Brisbane, Australia.
Ashley StewartSchool of Electrical Engineering and Computer Science, The University of Queensland, Brisbane, Australia.
Frederik J SteynRoyal Brisbane and Women's Hospital, Neurology Dept., Brisbane, Australia.
Saskia BollmannSchool of Electrical Engineering and Computer Science, The University of Queensland, Brisbane, Australia. saskia.bollmann@uq.edu.au.

Funding

Australian Research Council DP240102161Australian Research Council DP250103627Australian Research Council FT140100865, IC170100035, DP200103386, DP250103627Australian Research Council, Australia Linkage Grant LP200301393Austrian Science Fund 10.55776/PAT3786024Brain and Mind Centre, University of Sydney Research Development GrantFightMND ECR-202503-01848FightMND Mid-Career Research FellowshipMarie Sklodowska-Curie Actions, European Union 794298Motor Neurone Disease Research Australia PDF2112Motor Neurone Disease Research Australia TU2201National Health and Medical Research Council APP2029871National Health and Medical Research Council Boosting Dementia Research Leadership Fellowship (APP1135769)National Health and Medical Research Council, Australia APP 1088419, DP250103627University of Queensland Graduate School RTPUniversity of Sydney Fudan Brain and Intelligence Science Alliance Flagship Research Program, Moyira Elizabeth Vine Fund for Research into Schizophrenia Program
6 · The paper itself

Abstract

This dataset was acquired and curated to explore the spectrum of Motor Neuron Disease (MND) and Fronto-Temporal Dementia (FTD) with Ultra-High Field Magnetic Resonance Imaging (7 Tesla) and compare these to non-neurodegenerative disease controls (known colloquially as "The 7 T hEalthy Ageing study [7TEA]"). Twenty people living with neurodegenerative disease and 14 non-neurodegenerative controls underwent a comprehensive multimodal MRI protocol including structural, diffusion, quantitative MRI, resting state, and task fMRI, alongside cognitive testing and genetic screening. This dataset combines detailed imaging phenotypes with extensive clinical characterisations. It facilitates investigations into the spectrum of MND and FTD, has provided a basis for developing novel quantitative biomarkers, and supports the exploration of interactions between imaging features and clinical progression. The availability of this dataset supports various research avenues, from detailed hippocampal subfield analyses, network connectivity assessments, and multimodal genetic, cognitive, and imaging studies. The dataset is published on OpenNeuro (dataset ds007036) and is curated in the Brain Imaging Data Structure (BIDS) standard.

Indexed as

Amyotrophic Lateral SclerosisFrontotemporal DementiaMagnetic Resonance ImagingCognitionHumans

Identifiers

PMID42156779
PMCPMC13454292

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.